504 related articles for article (PubMed ID: 33995652)
1. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Alcaraz LB; Mallavialle A; David T; Derocq D; Delolme F; Dieryckx C; Mollevi C; Boissière-Michot F; Simony-Lafontaine J; Du Manoir S; Huesgen PF; Overall CM; Tartare-Deckert S; Jacot W; Chardès T; Guiu S; Roger P; Reinheckel T; Moali C; Liaudet-Coopman E
Theranostics; 2021; 11(13):6173-6192. PubMed ID: 33995652
[No Abstract] [Full Text] [Related]
2. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
3. SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
Alcaraz LB; Mallavialle A; Mollevi C; Boissière-Michot F; Mansouri H; Simony-Lafontaine J; Laurent-Matha V; Chardès T; Jacot W; Turtoi A; Roger P; Guiu S; Liaudet-Coopman E
Int J Cancer; 2023 Mar; 152(6):1243-1258. PubMed ID: 36346290
[TBL] [Abstract][Full Text] [Related]
4. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer.
Wolf M; Clark-Lewis I; Buri C; Langen H; Lis M; Mazzucchelli L
Am J Pathol; 2003 Apr; 162(4):1183-90. PubMed ID: 12651610
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis.
Derocq D; Prébois C; Beaujouin M; Laurent-Matha V; Pattingre S; Smith GK; Liaudet-Coopman E
Oncogene; 2012 Jun; 31(26):3202-12. PubMed ID: 22081071
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment.
Laurent-Matha V; Huesgen PF; Masson O; Derocq D; Prébois C; Gary-Bobo M; Lecaille F; Rebière B; Meurice G; Oréar C; Hollingsworth RE; Abrahamson M; Lalmanach G; Overall CM; Liaudet-Coopman E
FASEB J; 2012 Dec; 26(12):5172-81. PubMed ID: 22898924
[TBL] [Abstract][Full Text] [Related]
8. Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone.
Chlenski A; Guerrero LJ; Salwen HR; Yang Q; Tian Y; Morales La Madrid A; Mirzoeva S; Bouyer PG; Xu D; Walker M; Cohn SL
PLoS One; 2011; 6(9):e23880. PubMed ID: 21949685
[TBL] [Abstract][Full Text] [Related]
9. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.
Briozzo P; Morisset M; Capony F; Rougeot C; Rochefort H
Cancer Res; 1988 Jul; 48(13):3688-92. PubMed ID: 3378211
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a "secretome" analysis.
Volmer MW; Radacz Y; Hahn SA; Klein-Scory S; Stühler K; Zapatka M; Schmiegel W; Meyer HE; Schwarte-Waldhoff I
Proteomics; 2004 May; 4(5):1324-34. PubMed ID: 15188399
[TBL] [Abstract][Full Text] [Related]
11. S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells.
Kikuchi K; McNamara KM; Miki Y; Iwabuchi E; Kanai A; Miyashita M; Ishida T; Sasano H
Cell Oncol (Dordr); 2019 Feb; 42(1):67-80. PubMed ID: 30244410
[TBL] [Abstract][Full Text] [Related]
12. Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth.
Beaujouin M; Prébois C; Derocq D; Laurent-Matha V; Masson O; Pattingre S; Coopman P; Bettache N; Grossfield J; Hollingsworth RE; Zhang H; Yao Z; Hyman BT; van der Geer P; Smith GK; Liaudet-Coopman E
J Cell Sci; 2010 Oct; 123(Pt 19):3336-46. PubMed ID: 20826454
[TBL] [Abstract][Full Text] [Related]
13. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines.
Gilles C; Bassuk JA; Pulyaeva H; Sage EH; Foidart JM; Thompson EW
Cancer Res; 1998 Dec; 58(23):5529-36. PubMed ID: 9850090
[TBL] [Abstract][Full Text] [Related]
14. SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer.
Zhu A; Yuan P; Du F; Hong R; Ding X; Shi X; Fan Y; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B
Oncotarget; 2016 Nov; 7(47):76628-76634. PubMed ID: 27421134
[TBL] [Abstract][Full Text] [Related]
15. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers.
Anantaraju HS; Battu MB; Viswanadha S; Sriram D; Yogeeswari P
Mol Divers; 2016 May; 20(2):521-35. PubMed ID: 26563150
[TBL] [Abstract][Full Text] [Related]
17. SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity.
Barker TH; Baneyx G; Cardó-Vila M; Workman GA; Weaver M; Menon PM; Dedhar S; Rempel SA; Arap W; Pasqualini R; Vogel V; Sage EH
J Biol Chem; 2005 Oct; 280(43):36483-93. PubMed ID: 16115889
[TBL] [Abstract][Full Text] [Related]
18. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
19. Vasoinhibins, N-terminal mouse prolactin fragments, participate in mammary gland involution.
Ishida M; Maehara M; Watanabe T; Yanagisawa Y; Takata Y; Nakajima R; Suzuki M; Harigaya T
J Mol Endocrinol; 2014 Jun; 52(3):279-87. PubMed ID: 24598201
[TBL] [Abstract][Full Text] [Related]
20. Type I collagen-deficient Mov-13 mice do not retain SPARC in the extracellular matrix: implications for fibroblast function.
Iruela-Arispe ML; Vernon RB; Wu H; Jaenisch R; Sage EH
Dev Dyn; 1996 Oct; 207(2):171-83. PubMed ID: 8906420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
